BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Epithelial tumours of the thymus (thymoma, thymic carcinoma) are rare tumours of the anterior mediastinum.

So far, EGFR mutational status of different subtypes of epithelial tumours of the thymus has been analyzed only inappropriately.

Thus EGFR-expression in thymic tumours does not rely on mutations in critical functional (activation) domains of the EGFR-gene.

[MeSH-major] Genes, erbB-1. Thymoma / genetics. Thymus Neoplasms / genetics

MedlinePlus Health Information. consumer health - Thymus Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16919868.001).

[ISSN] 0304-3835

[Journal-full-title] Cancer letters

[ISO-abbreviation] Cancer Lett.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Ireland

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

It has been reported that (-)-Menthol can inhibit the growth of rat liver epithelial tumor cells and is a potent chemopreventive agent.

[MeSH-major] Menthol / pharmacology. NF-kappa B / biosynthesis. Stomach Neoplasms / drug therapy. Topoisomerase Inhibitors

[MeSH-minor] Antigens, Neoplasm / biosynthesis. Antigens, Neoplasm / genetics. Cell Death / drug effects. Cell Line, Tumor. Cell Survival / drug effects. DNA Damage. DNA Topoisomerases / biosynthesis. DNA Topoisomerases / genetics. DNA Topoisomerases, Type I / biosynthesis. DNA Topoisomerases, Type I / genetics. DNA Topoisomerases, Type II / biosynthesis. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / antagonists & inhibitors. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Gene Expression. Humans. Stereoisomerism. Topoisomerase I Inhibitors. Topoisomerase II Inhibitors

MedlinePlus Health Information. consumer health - Stomach Cancer.

Hazardous Substances Data Bank. MENTHOL .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16158947.001).

[ISSN] 0250-7005

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / NF-kappa B; 0 / Topoisomerase I Inhibitors; 0 / Topoisomerase II Inhibitors; 0 / Topoisomerase Inhibitors; 1490-04-6 / Menthol; EC 5.99.1.- / DNA Topoisomerases; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; EC 5.99.1.3 / DNA topoisomerase II beta

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases.

BACKGROUND & AIMS: The clinical outcomes for endoscopic submucosal dissection (ESD), a novel endoluminal surgery for gastrointestinal neoplasm in the colorectum, are reported.

METHODS: ESD was performed on 186 consecutive patients with 200 colorectal epithelial neoplasms who had preoperative diagnoses of mucosal or slight submucosally invasive neoplasms.

The rate of en bloc resection was 91.5% (183/200), and en bloc resection with tumor-free lateral/basal margins (R0 resection) was 70.5% (141/200).

Two multiple-piece resections of 111 tumors (1.8%), which were successfully followed by colonoscopy (median follow-up, 18 months; range, 12-60 months), were found as locally recurrent tumors 2 and 21 months after ESD.

However, when considering the risks and benefits, piecemeal endoscopic resection or colorectal resection might be more appropriate for some subgroups of large flat neoplasms or those with submucosal fibrosis.

[MeSH-major] Colonoscopy. Colorectal Neoplasms / surgery

MedlinePlus Health Information. consumer health - Colonoscopy.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Clin Gastroenterol Hepatol. 2007 Jun;5(6):674-7 [17544994.001]

(PMID = 17466600.001).

[ISSN] 1542-7714

[Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

[ISO-abbreviation] Clin. Gastroenterol. Hepatol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.

Data regarding expression in renal epithelial tumors other than clear cell renal cell carcinoma (RCC) are limited, conflicting, from tissue microarrays, and do not encompass the entire spectrum or novel uncommon variants.

Conventional sections from 200 renal tumors comprising clear cell RCC (n=30), oncocytoma (n=17), papillary RCC (n=30), chromophobe RCC (n=50), urothelial carcinomas (n=30), collecting duct carcinomas (n=5), renal tumors with Xp11.2 translocation (n=15), tubulocystic carcinoma (n=19), and mucinous tubular spindle cell carcinoma (n=4) were immunostained for Pax 2 and CA IX.

Clear cell RCC (30/30, 100%), urothelial carcinoma (27/30, 90%), papillary RCC (17/30, 57%), and renal tumors with Xp11.2 translocation (6/15, 40%) exhibited membranous immunoreactivity with CA IX, whereas the other subtypes were nonreactive.

This suggests potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma (positive) from chromophobe RCC (negative), (ii) clear cell RCC and papillary RCC (positive) from renal tumors with Xp11.2 translocation (negative), and (iii) high-grade clear cell RCC (positive) from urothelial carcinoma (negative).

[MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / analysis. Carbonic Anhydrases / metabolism. Kidney Neoplasms / diagnosis. Neoplasms, Glandular and Epithelial / pathology. PAX2 Transcription Factor / metabolism

MedlinePlus Health Information. consumer health - Kidney Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18941400.001).

[ISSN] 1532-0979

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Canine cutaneous neoplasms: prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous neoplasms in dogs from Zimbabwe.

Sixty per cent (540/900) of the cases were tumours and 40% (360/900) were non-neoplastic inflammatory or degenerative diseases.

Thirty different histological types of tumour were diagnosed.

The prevalence of epithelial, mesenchymal, lymphohistiocytic and melanocytic tumours was 39.4%, 44.4%, 7.4% and 8.7%, respectively.

The 10 most common tumours, comprising 73.7% of all cutaneous neoplasms, were mast cell tumours, squamous cell carcinomas, perianal gland adenomas, lymphomas, benign melanomas, haemangiosarcomas, sebaceous gland adenomas, fibrosarcomas, lipomas and malignant melanomas.

The prevalence of various neoplasms, age of affected dogs and sites of occurrence were similar to surveys in other countries, except that in Zimbabwe there was a greater prevalence of lymphomas and of tumours associated with increased exposure to ultraviolet light (squamous cell carcinomas, haemangiosarcomas and melanomas).

For all classes of tumours the sex of the dog did not have any significant influence on the likelihood of developing a tumour.

For a dog diagnosed with a tumour located on the trunk, the tumour was significantly more likely to be an epithelial tumour than a non-epithelial tumour The occurrence of melanocytic tumours on the trunk was significantly lower than at other sites.

Lymphohistiocytic tumours were 10 times more likely to occur at multiple locations as opposed to single locations.

[MeSH-major] Dog Diseases / epidemiology. Dog Diseases / pathology. Skin Neoplasms / veterinary

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16108522.001).

[ISSN] 1019-9128

[Journal-full-title] Journal of the South African Veterinary Association

[ISO-abbreviation] J S Afr Vet Assoc

[Language] eng

[Publication-type] Journal Article

[Publication-country] South Africa

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Trials of the biologic prepared from this secretion in salmons with epithelioma, guinea pigs with affected skin, and mice with transplantable tumors demonstrated a good therapeutic effect of the biologic.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16240755.001).

[ISSN] 1026-3470

[Journal-full-title] Izvestiia Akademii nauk. Seriia biologicheskaia

[ISO-abbreviation] Izv. Akad. Nauk. Ser. Biol.

[Language] RUS

[Publication-type] English Abstract; Journal Article

[Publication-country] Russia (Federation)

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protective Agents; 0 / Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVES: Expression of uPA mRNA is massively up-regulated in the stroma of poorly differentiated ovarian tumors.

We hypothesized that this expression was induced by paracrine signals from the epithelial tumor cells, and established an in vitro model of ovarian cancer microenvironment to study intercellular cross-talk.

[MeSH-major] Adenocarcinoma / pathology. Cell Communication / physiology. Fibroblasts / cytology. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis. Stromal Cells / cytology. Urokinase-Type Plasminogen Activator / genetics

[MeSH-minor] Cell Line, Tumor. Coculture Techniques. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Up-Regulation

Genetic Alliance. consumer health - Ovarian cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19631971.001).

[ISSN] 1095-6859

[Journal-full-title] Gynecologic oncology

[ISO-abbreviation] Gynecol. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The type AB thymoma is an epithelial neoplasm composed of both type A (lymphocyte-poor) and type B (lymphocyte-rich) areas.

[MeSH-major] Lymphomatoid Papulosis / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology. Thymoma / pathology. Thymus Neoplasms / pathology

[MeSH-minor] Aged, 80 and over. Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Blotting, Southern. CD8-Positive T-Lymphocytes / immunology. Chemokines / metabolism. Humans. Immunohistochemistry. Male. Polymerase Chain Reaction. Receptors, Chemokine / metabolism

Genetic Alliance. consumer health - Lymphomatoid papulosis.

MedlinePlus Health Information. consumer health - Skin Cancer.

MedlinePlus Health Information. consumer health - Thymus Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19542925.001).

[ISSN] 1533-0311

[Journal-full-title] The American Journal of dermatopathology

[ISO-abbreviation] Am J Dermatopathol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Chemokines; 0 / Receptors, Chemokine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of neurotrophin receptors in surgically resected thymic epithelial tumors.

OBJECTIVE: Neurotrophins are known to exert a variety of pleiotropic responses in different target tissues, but little is known about their effect on thymic epithelial tumors.

Therefore, we analyzed the expression of neurotrophin receptors in surgically resected thymic epithelial tumors and evaluated their clinical relevance.

METHODS: The expression of neurotrophin receptors (Trk-A, Trk-B, Trk-C and p75(NTR)) in thymic epithelial tumors was evaluated in 99 consecutive patients based on immunohistochemical staining.

RESULTS: Thymic tumors were classified as type A (n=6), AB (n=21), B1 (n=15), B2 (n=24), B3 (n=22) or C (n=11).

All tumors, except one type C thymoma, demonstrated cytoplasmic Trk-A immunostaining, and no thymic tumors showed Trk-B or Trk-C immunoreactivity. p75(NTR) immunostaining demonstrated characteristic patterns according to the WHO subtypes of thymomas.

All type A and type AB thymomas showed p75(NTR) immunoreactivity, except one type A tumor.

Tumor-related survival at 5 and 10 years was 95.5 and 89.5%, respectively, in p75(NTR)-positive thymomas and 82.8 and 77.2%, respectively, in p75(NTR)-negative thymomas; however, the differences were not statistically significant (P=0.14).

Further study of p75(NTR) expression may aid in understanding the biology of thymic epithelial tumors.

[MeSH-major] Receptors, Nerve Growth Factor / analysis. Thymoma / chemistry. Thymus Neoplasms / chemistry

[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis. Prognosis. Receptor, trkA / analysis. Receptor, trkB / analysis. Receptor, trkC / analysis. Receptors, Growth Factor / analysis. Survival Analysis. Thymus Gland / metabolism. Thymus Gland / pathology

MedlinePlus Health Information. consumer health - Thymus Cancer.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16125946.001).

[ISSN] 1010-7940

[Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

[ISO-abbreviation] Eur J Cardiothorac Surg

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / NGFR protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / Receptor, trkB; EC 2.7.10.1 / Receptor, trkC

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Neuroendocrine carcinoma of the non-small cell type of the ovary is a rare aggressive tumor, interestingly associated with either a surface epithelial tumor or teratoma.

Pathology examination showed a 6.5 cm in greatest dimension ovarian tumor composed of neuroendocrine carcinoma of the non-small cell type and serous carcinoma.

[MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

Genetic Alliance. consumer health - Ovarian small cell carcinoma.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17229461.001).

[ISSN] 0090-8258

[Journal-full-title] Gynecologic oncology

[ISO-abbreviation] Gynecol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The majority of ovarian masses in childhood and adolescence are non-epithelial in origin, with a predominance of germ cell tumors, while epithelial neoplasms comprise a small proportion of the total (approximately 15-20%).

Careful evaluation of the remaining pathological features of the tumor is needed in order to avoid misinterpreting this relatively non-specific finding as a feature of malignancy.

[MeSH-major] Cystadenoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17089585.001).

[ISSN] 0390-6663

[Journal-full-title] Clinical and experimental obstetrics & gynecology

[ISO-abbreviation] Clin Exp Obstet Gynecol

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Italy

[Number-of-references] 11

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Expression of type 1 and type 2 mucins in colonic epithelial tumors].

[MeSH-major] Adenocarcinoma. Antigens, Neoplasm / biosynthesis. Colonic Neoplasms. Intestinal Mucosa. Mucins / biosynthesis

[MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin-1. Mucin-2. Prognosis

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17642184.001).

[ISSN] 0004-1955

[Journal-full-title] Arkhiv patologii

[ISO-abbreviation] Arkh. Patol.

[Language] rus

[Publication-type] English Abstract; Journal Article

[Publication-country] Russia (Federation)

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Epithelial tumors displayed the highest age specific incidence rate, followed by germ cell tumors.

Serous epithelial tumors were the most common in the epithelial group.

[MeSH-major] Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / pathology

[MeSH-minor] Adult. Age Distribution. Age of Onset. Aged. Biopsy, Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Iran / epidemiology. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / pathology. Prognosis. Registries. Survival Analysis

Genetic Alliance. consumer health - Ovarian cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20433224.001).

[ISSN] 1735-3947

[Journal-full-title] Archives of Iranian medicine

[ISO-abbreviation] Arch Iran Med

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Iran

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Lacrimal gland epithelial tumors].

[Transliterated title] Tumeurs épithéliales de la glande lacrymale.

Epithelial tumors of the lacrimal gland account for 50% of the expansive lesions of the lacrimal fossa.

[MeSH-major] Eye Neoplasms / surgery. Lacrimal Apparatus / surgery. Neoplasms, Glandular and Epithelial / pathology

MedlinePlus Health Information. consumer health - Eye Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.

(PMID = 20303130.001).

[ISSN] 1773-0619

[Journal-full-title] Neuro-Chirurgie

[ISO-abbreviation] Neurochirurgie

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] France

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.

Here, we propose a new model for understanding the Warburg effect in tumor metabolism.

Our hypothesis is that epithelial cancer cells induce the Warburg effect (aerobic glycolysis) in neighboring stromal fibroblasts.

Epithelial cancer cells could then take up these energy-rich metabolites and use them in the mitochondrial TCA cycle, thereby promoting efficient energy production (ATP generation via oxidative phosphorylation), resulting in a higher proliferative capacity.

In this alternative model of tumorigenesis, the epithelial cancer cells instruct the normal stroma to transform into a wound-healing stroma, providing the necessary energy-rich micro-environment for facilitating tumor growth and angiogenesis.

In essence, the fibroblastic tumor stroma would directly feed the epithelial cancer cells, in a type of host-parasite relationship.

In this scenario, the epithelial tumor cells "corrupt" the normal stroma, turning it into a factory for the production of energy-rich metabolites.

This alternative model is still consistent with Warburg's original observation that tumors show a metabolic shift towards aerobic glycolysis.

Importantly, a loss of stromal Cav-1 in human breast cancers is associated with tumor recurrence, metastasis, and poor clinical outcome.

Thus, an absence of stromal Cav-1 may be a biomarker for the "Reverse Warburg Effect," explaining its powerful predictive value.

[MeSH-major] Breast Neoplasms / metabolism. Fibroblasts / metabolism. Glycolysis

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19923890.001).

[ISSN] 1551-4005

[Journal-full-title] Cell cycle (Georgetown, Tex.)

[ISO-abbreviation] Cell Cycle

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30-CA-56036; United States / NIAMS NIH HHS / AR / R01-AR-055660; United States / NCI NIH HHS / CA / R01-CA-098779; United States / NCI NIH HHS / CA / R01-CA-107382; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01-CA-70896; United States / NCI NIH HHS / CA / R01-CA-75503; United States / NCI NIH HHS / CA / R01-CA-80250; United States / NCI NIH HHS / CA / R01-CA-86072

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Annexins; 0 / Caveolin 1; 0 / Tenascin; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.7.1.40 / Pyruvate Kinase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization.

Our objective was to compare the genetic abnormalities in the primary tumors of epithelial ovarian cancer and their associated secondary peritoneal implants using comparative genomic hybridization (CGH).

Dissected tissue samples from the primary tumor and from the metastatic peritoneal implant were obtained at initial surgical staging and analyzed in each case.

We used CGH as this technique allows the entire genome of the tumor to be examined simultaneously for chromosomal imbalances without the need for tissue culture or targeting of specific loci.

Comparing the genomes of the primary tumors with the metastatic samples showed four cases with a balanced metastatic CGH profile while the primary site was aberrant.

The cytogenetic patterns in six of the seven primary tumors showed complex karyotypic changes, unlike the inconsistent findings that were associated with the secondary sites.

Such genomic heterogeneity between the primary and secondary sites may indicate that the secondary peritoneal implants are de novo carcinogenesis occurrences.

[MeSH-major] Chromosome Aberrations. DNA Damage. DNA, Neoplasm / genetics. Neoplasm Metastasis / genetics. Nucleic Acid Hybridization. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

[MeSH-minor] Female. Humans. Karyotyping. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / secondary

Genetic Alliance. consumer health - Ovarian cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15823109.001).

[ISSN] 1048-891X

[Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

[ISO-abbreviation] Int. J. Gynecol. Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Neoplasm

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor.

OBJECTIVE: Adenofibroma is a form of mixed mesodermal tumor in which epithelial and stromal components are benign, and usually arises in the endometrium of postmenopausal women.

CONCLUSION: We suggest that uterine adenofibromas with lipomatous areas belong to the family of mixed tumor of Mullerian origin.

[MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology. Mixed Tumor, Mullerian / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18236054.001).

[ISSN] 1432-0711

[Journal-full-title] Archives of gynecology and obstetrics

[ISO-abbreviation] Arch. Gynecol. Obstet.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Receptor tyrosine kinases (RTK) remain an area of therapeutic interest because of their role in epithelial tumors, and experimental models specific to these targets are highly desirable.

A CD8HER2 fusion protein was shown to form disulfide-mediated homodimers and to transform fibroblasts and epithelial cells.

CD8RTK fusion proteins transform rat kidney epithelial cells and impart phenotypes that may reflect signaling specificity inherent in the native receptors.

Transgenic expression of CD8HER2 and CD8Met in mice resulted in the formation of salivary and mammary gland tumors.

The transgenic tumors allow the derivation of allograft tumors and cell lines that are sensitive to inhibition by small molecule kinase inhibitors.

This approach provides excellent cell and tumor models for the characterization of signaling properties of diverse RTKs and for the evaluation of rationally designed antagonists targeting these kinases.

[MeSH-major] Antigens, CD8 / metabolism. Gene Expression Regulation, Neoplastic / physiology. Mammary Neoplasms, Animal / genetics. Receptor, ErbB-2 / metabolism. Recombinant Fusion Proteins / genetics. Salivary Gland Neoplasms / genetics

[MeSH-minor] Animals. Blotting, Western. Cell Transformation, Neoplastic / genetics. Dimerization. Disease Models, Animal. Disulfides / pharmacology. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Fibroblasts / cytology. Fibroblasts / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, Transgenic. Peptide Fragments / immunology. Plasmids. Proto-Oncogene Proteins c-met / genetics. Proto-Oncogene Proteins c-met / metabolism. Rats. Receptor Protein-Tyrosine Kinases / metabolism. Transfection

MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16818516.001).

[ISSN] 1535-7163

[Journal-full-title] Molecular cancer therapeutics

[ISO-abbreviation] Mol. Cancer Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD8; 0 / CD8 antigen, alpha chain; 0 / Disulfides; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, ErbB-2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs.

Ex vivo analysis of signaling pathways operating in tumor tissue is complicated by the three-dimensional structure, in particular by stroma-epithelial interactions.

Studies performed with pure populations of tumor cells usually do not take into account this issue.

One possibility to preserve the tissue architecture is the use of tumor slices.

By using precision cut slices of defined thickness, we were able to establish culture conditions for tumor material obtained from MMTV-neu transgenic mice, which allow the study of the action of cytokines and cytotoxic drugs for up to 24 h.

The slices were also a convenient source for the establishment of explant cultures of tumor epithelial cells.

It is concluded that cultivation of precision-cut tumor slices provides a convenient way for the ex vivo molecular analysis of MMTV-neu tumor tissue under conditions which closely simulate the situation in vivo and can provide an alternative to in vivo experiments.

[MeSH-major] Cytokines / pharmacology. Cytostatic Agents / pharmacology. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / pathology. Tissue Culture Techniques

[MeSH-minor] Animals. Doxorubicin / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / pathology. Interferon Regulatory Factor-1 / drug effects. Interferon Regulatory Factor-1 / metabolism. Mammary Tumor Virus, Mouse. Mice. Mice, Transgenic. Receptor, ErbB-2 / metabolism. STAT1 Transcription Factor / drug effects. STAT1 Transcription Factor / metabolism. Signal Transduction / drug effects. Signal Transduction / physiology. Suppressor of Cytokine Signaling 1 Protein. Suppressor of Cytokine Signaling Proteins / drug effects. Suppressor of Cytokine Signaling Proteins / metabolism. Tumor Cells, Cultured

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOXORUBICIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell Biol Toxicol. 2002;18(3):205-19 [12083426.001]

[Cites] Life Sci. 1995;57(21):1887-901 [7475939.001]

[Cites] J Biol Chem. 2008 Aug 8;283(32):22089-96 [18524780.001]

[Cites] Clin Cancer Res. 2004 Dec 15;10(24):8697-703 [15623655.001]

[Cites] Int J Biochem Cell Biol. 2007;39(11):1987-94 [17719831.001]

[Cites] Liver Int. 2006 Jun;26(5):604-12 [16762006.001]

[Cites] J Virol. 2008 Jan;82(2):999-1010 [17977977.001]

[Cites] Eur J Biochem. 1999 Jan;259(1-2):25-31 [9914471.001]

[Cites] J Pharmacol Toxicol Methods. 1997 Oct;38(2):59-69 [9403776.001]

[Cites] Gynecol Oncol. 2007 Sep;106(3):614-21 [17602728.001]

[Cites] Nat Rev Cancer. 2006 Mar;6(3):204-16 [16498443.001]

[Cites] Respir Res. 2007 Jun 14;8:43 [17567922.001]

[Cites] Toxicology. 2000 Nov 16;153(1-3):221-53 [11090959.001]

[Cites] BMC Cancer. 2007 Jul 25;7:136 [17651480.001]

[Cites] J Cell Sci. 1989 Jul;93 ( Pt 3):491-500 [2606940.001]

[Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62 [12209125.001]

[Cites] Gynecol Oncol. 2008 Mar;108(3):591-7 [18177927.001]

[Cites] BMC Cancer. 2008 Apr 24;8:119 [18435859.001]

[Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]

[Cites] Nat Rev Cancer. 2007 May;7(5):389-97 [17446858.001]

[Cites] J Biol Chem. 2004 Dec 17;279(51):53272-81 [15489221.001]

[Cites] Traffic. 2007 Dec;8(12):1815-28 [17892529.001]

[Cites] Cell Biol Toxicol. 1998 Jun;14(3):175-90 [9689491.001]

[Cites] Breast Cancer Res. 2003;5(3):130-5 [12793893.001]

[Cites] In Vitro Cell Dev Biol Anim. 2004 Jan-Feb;40(1-2):14-21 [15180438.001]

[Cites] Cell Tissue Res. 2008 Jun;332(3):489-98 [18386065.001]

[Cites] Cell Biol Int. 1999;23(3):157-61 [10562436.001]

[Cites] In Vitro Cell Dev Biol Anim. 2002 Jun;38(6):326-33 [12513120.001]

[Cites] BMC Cancer. 2006 Apr 07;6:86 [16603054.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 [1359541.001]

(PMID = 19533258.001).

[ISSN] 1543-706X

[Journal-full-title] In vitro cellular & developmental biology. Animal

[ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.

[Language] eng

[Grant] Austria / Austrian Science Fund FWF / / W 1101

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Cytokines; 0 / Cytostatic Agents; 0 / Interferon Regulatory Factor-1; 0 / STAT1 Transcription Factor; 0 / Socs1 protein, mouse; 0 / Stat1 protein, mouse; 0 / Suppressor of Cytokine Signaling 1 Protein; 0 / Suppressor of Cytokine Signaling Proteins; 80168379AG / Doxorubicin; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A cross-link between protein kinase A and Rho-family GTPases signaling mediates cell-cell adhesion and actin cytoskeleton organization in epithelial cancer cells.

Disassembly of the apical junctional complex (AJC) together with actin cytoskeleton alterations are among the initial events for the development of epithelial cancer.

Thus, our findings demonstrate a central role of a regulatory cascade that integrates PKA and Rho-family GTPases in the AJC disassembly and actin organization in tumor epithelial cells.

[MeSH-major] Adenocarcinoma / pathology. Cell Adhesion. Cyclic AMP-Dependent Protein Kinases / metabolism. Cytoskeleton / metabolism. Epithelial Cells / ultrastructure. Signal Transduction. rho GTP-Binding Proteins / metabolism

[MeSH-minor] Actins / metabolism. Caco-2 Cells. Colonic Neoplasms / pathology. Humans. Intercellular Junctions / metabolism

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18791066.001).

[ISSN] 1521-0103

[Journal-full-title] The Journal of pharmacology and experimental therapeutics

[ISO-abbreviation] J. Pharmacol. Exp. Ther.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Actins; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.5.2 / rho GTP-Binding Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunohistochemical evaluation of canine ovarian tumors.

Canine ovarian tumors (epithelial tumor, sex-cord stromal tumor, germ cell tumor) classifying into 9 histological types were examined immunohistochemically using placental alkaline phosphatase (PLAP), cytokeratin7 (CK7), desmin, S100, AE1/AE3, inhibin alpha, vimentin, and alfa feto-protein (AFP).

The papillary and tubular types observed in epithelial tumors were immunoreactive for desmin and AE1/AE3.

The solid type, nest type, cord type, palisade type, cystic type and spindle type, which were observed in sex-cord stromal tumors, showed a positive immunoreaction for S100 but little or no positive immunoreaction for inhibin alpha with an exception of positive result in the palisade type.

Most of the sex-cord stromal tumors were AE1/AE3-positive except for the palisade type.

In the cobblestone type observed in germ cell tumors, only vimentin and AFP were positive.

The present study elucidated the detailed histological and immunohistochemical characteristics of canine ovarian tumors.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17675800.001).

[ISSN] 0916-7250

[Journal-full-title] The Journal of veterinary medical science

[ISO-abbreviation] J. Vet. Med. Sci.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Japan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: Diagnostic enucleation and histopathologic studies revealed findings consistent with primary intraocular lymphoma including intraretinal, subretinal, and subretinal pigment epithelial tumor cells without involvement of the choroid.

[MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Retinal Neoplasms / diagnosis. Vitreous Body / pathology

MedlinePlus Health Information. consumer health - Eye Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15767087.001).

[ISSN] 0002-9394

[Journal-full-title] American journal of ophthalmology

[ISO-abbreviation] Am. J. Ophthalmol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.

OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in tumor metastasis and invasion.

It has been suggested that both enzymes play a role the progression of epithelial ovarian cancer and they have been investigated as potential biomarkers for ovarian cancer.

Tissue specimens were divided into four groups: normal ovary, benign neoplasm, early-stage (I/II) cancer, and late-stage (III/IV) cancer.

CONCLUSIONS: CB activity is associated with invasive ovarian neoplasm.

[MeSH-major] Cathepsin B / metabolism. Cathepsin D / metabolism. Ovarian Neoplasms / enzymology. Ovary / enzymology

[MeSH-minor] Female. Humans. Isoenzymes. Tumor Cells, Cultured

Genetic Alliance. consumer health - Ovarian cancer.

Genetic Alliance. consumer health - Ovarian epithelial cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16202931.001).

[ISSN] 1556-7117

[Journal-full-title] Journal of the Society for Gynecologic Investigation

[ISO-abbreviation] J. Soc. Gynecol. Investig.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant tumours of childhood in Zaria.

BACKGROUND: The increased prevalence of hitherto uncommon tumours in children in our geographic setting formed the basis for this study.

MATERIALS AND METHODS: An eight year (2000-2007) consecutive analysis of malignant tumours in children ages 0 to 15 years in a referral University laboratory.

Tumours were characterised histologically into tissues of origin and categorised into three age groups; <1 year, 1-5 years and 6-15 years.

RESULT: 189 children with malignant tumours were analysed.

Tumours of mesenchymal origin were the commonest (115: 60.8%) while epithelial tumours including germ cell tumours accounted for 74 (39.2%) cases.

The age group 1-5 years had the highest epithelial tumours while age group 6-15 years had the most tumours with 102 (54%) cases overall.

The five commonest tumours over-all were rhabdomyosarcoma, Burkitt lymphoma, retinoblastoma, non-Hodgkin's lymphoma and nephroblastoma.

Germ cell tumours affected the ovary predominantly and two of the endodermal sinus tumour cases were seen in the testis of an eighteen month child and sacrococcygeum of a 5 year old girl, respectively.

The vascular tumours included epithelioid haemangioendothelioma, haemangioblastoma and Dabska tumour and they accounted for (5.8%) of all tumours seen.

The commonest sites of occurrence of these tumours were the oculo-orbital, jaw, head and neck regions with 82 cases (43.4%) while lymph nodes were involved in 31 (16.4%) cases.

CONCLUSION: The distribution and occurrence of malignant tumours in children is age related.

Lymphomas were the commonest tumours overall while retinoblastoma and Burkitt lymphoma were the commonest tumours affecting children below 5 years and 6-10 years old, respectively, in our centre.

The head region and lymph nodes were the sites of predilection for majority of these tumours.

[MeSH-major] Lymphoma / epidemiology. Neoplasms / epidemiology. Neoplasms / pathology. Retinal Neoplasms / epidemiology. Retinoblastoma / epidemiology

MedlinePlus Health Information. consumer health - Cancer in Children.

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19661660.001).

[ISSN] 0974-5998

[Journal-full-title] African journal of paediatric surgery : AJPS

[ISO-abbreviation] Afr J Paediatr Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] Nigeria

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The membrane mucin MUC4 (human) is abundantly expressed in many epithelia, where it is proposed to play a protective role, and is overexpressed in some epithelial tumors.

The roles of MUC4 in tumors suggest that it may be valuable as a tumor marker or target for therapy.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]

[Cites] FASEB J. 2008 Aug;22(8):3035-45 [18492726.001]

[Cites] Biochim Biophys Acta. 2008 Oct;1783(10):1728-36 [18573283.001]

[Cites] Br J Cancer. 2009 Jan 27;100(2):344-51 [19127263.001]

[Cites] Exp Cell Res. 2009 Feb 15;315(4):638-48 [19038249.001]

[Cites] Cancer Res. 2009 Apr 1;69(7):2845-52 [19293191.001]

[Cites] Crit Rev Oncog. 2008;14(2-3):177-96 [19409062.001]

[Cites] J Cell Biochem. 2009 Jul 1;107(4):797-802 [19388004.001]

[Cites] J Biol Chem. 2003 May 30;278(22):20338-44 [12668667.001]

[Cites] J Biol Chem. 2003 Aug 8;278(32):30142-7 [12748185.001]

[Cites] J Biol Chem. 2003 Sep 19;278(38):36942-52 [12855694.001]

[Cites] Biochem J. 2004 Feb 1;377(Pt 3):701-8 [14583090.001]

[Cites] Cancer Res. 2004 Jan 15;64(2):622-30 [14744777.001]

[Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]

[Cites] Mod Pathol. 2004 Feb;17(2):150-7 [14657954.001]

[Cites] Laryngoscope. 2004 Aug;114(8 Pt 2 Suppl 101):1-32 [15284539.001]

[Cites] Oncogene. 2004 Jul 29;23(34):5729-38 [15184872.001]

[Cites] Inflammation. 2004 Apr;28(2):67-76 [15379212.001]

[Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]

[Cites] Cancer. 2001 Oct 15;92(8):2148-57 [11596032.001]

[Cites] Curr Biol. 2001 Nov 13;11(22):1739-48 [11719215.001]

[Cites] Am J Respir Cell Mol Biol. 2002 Apr;26(4):447-52 [11919081.001]

[Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]

[Cites] Prog Nucleic Acid Res Mol Biol. 2002;71:149-85 [12102554.001]

[Cites] Int J Cancer. 2002 Jun 20;99(6):783-91 [12115478.001]

[Cites] Eur J Biochem. 2002 Aug;269(15):3637-44 [12153560.001]

[Cites] Cell Microbiol. 2002 Aug;4(8):515-29 [12174086.001]

[Cites] J Biol Chem. 2002 Aug 30;277(35):32258-67 [12077147.001]

[Cites] Oncogene. 2002 Oct 24;21(49):7524-32 [12386815.001]

[Cites] Biochem J. 2002 Nov 15;368(Pt 1):41-8 [12186632.001]

[Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L671-9 [12495942.001]

[Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]

[Cites] Nature. 2003 Mar 20;422(6929):322-6 [12646923.001]

[Cites] Biochem Pharmacol. 2003 May 1;65(9):1419-25 [12732353.001]

[Cites] Cancer Res. 1999 May 1;59(9):2229-36 [10232613.001]

[Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]

[Cites] J Biol Chem. 1980 Jan 25;255(2):783-90 [7356644.001]

[Cites] J Biol Chem. 1980 Dec 25;255(24):12051-9 [7440586.001]

[Cites] J Biol Chem. 1984 Apr 25;259(8):4866-77 [6715325.001]

[Cites] Biochem J. 1990 Jan 1;265(1):121-9 [2302161.001]

[Cites] J Biol Chem. 1990 May 25;265(15):8505-10 [2111320.001]

[Cites] Biochem Biophys Res Commun. 1991 Mar 15;175(2):414-22 [1673336.001]

[Cites] J Biol Chem. 1992 Aug 15;267(23):16341-6 [1379596.001]

[Cites] J Biol Chem. 1994 Apr 22;269(16):11950-5 [8163496.001]

[Cites] Cell. 1994 Jul 15;78(1):5-8 [8033211.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6 [8058768.001]

[Cites] J Biol Chem. 1997 Dec 26;272(52):33245-54 [9407114.001]

[Cites] Biochem J. 1998 Mar 1;330 ( Pt 2):737-44 [9480884.001]

[Cites] Biochem J. 1998 Oct 15;335 ( Pt 2):457-63 [9761747.001]

[Cites] Clin Cancer Res. 1998 Nov;4(11):2669-76 [9829729.001]

[Cites] J Biol Chem. 1998 Dec 25;273(52):35228-37 [9857062.001]

[Cites] J Biol Chem. 1999 Feb 26;274(9):5263-6 [10026131.001]

[Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):325-33 [10024507.001]

[Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]

[Cites] J Biol Chem. 2000 Jun 9;275(23):17800-7 [10837499.001]

[Cites] Int J Cancer. 2000 Aug 15;87(4):480-6 [10918186.001]

[Cites] Oncogene. 2000 Sep 7;19(38):4354-61 [10980611.001]

[Cites] J Cell Physiol. 2000 Nov;185(2):310-6 [11025453.001]

[Cites] J Biol Chem. 2000 Oct 27;275(43):33929-36 [10938282.001]

[Cites] Biochem J. 2000 Jul 15;349(Pt 2):641-9 [10880365.001]

[Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]

[Cites] J Biol Chem. 2001 Jun 15;276(24):21885-94 [11283019.001]

[Cites] J Biol Chem. 2001 Aug 17;276(33):30923-33 [11418607.001]

[Cites] Biochem J. 2005 Feb 15;386(Pt 1):35-45 [15461591.001]

[Cites] Cancer Res. 2005 Jan 15;65(2):473-82 [15695389.001]

[Cites] J Clin Pathol. 2005 Aug;58(8):845-52 [16049287.001]

[Cites] Oncogene. 2005 Sep 8;24(40):6143-54 [16007204.001]

[Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]

[Cites] Respir Res. 2006;7:39 [16551361.001]

[Cites] Biosci Rep. 2006 Feb;26(1):55-67 [16779668.001]

[Cites] Mol Biol Cell. 2006 Jul;17(7):2931-41 [16624867.001]

[Cites] J Biol Chem. 2006 Jul 14;281(28):19310-9 [16690615.001]

[Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]

[Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]

[Cites] J Biol Chem. 2006 Sep 29;281(39):29411-20 [16891313.001]

[Cites] Oncogene. 2007 Jan 4;26(1):30-41 [16799633.001]

[Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]

[Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]

[Cites] Biochem J. 2007 Feb 15;402(1):81-91 [17037983.001]

[Cites] Arch Pathol Lab Med. 2007 Apr;131(4):593-8 [17425390.001]

[Cites] J Biol Chem. 2007 Aug 3;282(31):22638-50 [17553805.001]

[Cites] Annu Rev Physiol. 2008;70:431-57 [17850209.001]

(PMID = 20001800.001).

[ISSN] 1744-8301

[Journal-full-title] Future oncology (London, England)

[ISO-abbreviation] Future Oncol

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA052498-17; United States / NCI NIH HHS / CA / CA52498; United States / NCI NIH HHS / CA / R01 CA052498-17; United States / NCI NIH HHS / CA / R01 CA052498; United States / NCI NIH HHS / CA / CA052498-16; United States / NCI NIH HHS / CA / R01 CA052498-16

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4

[Number-of-references] 86

[Other-IDs] NLM/ NIHMS171897; NLM/ PMC2825673

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Pelvic examination realized under anesthetic revealed a tumor mass occupying the uterine cervix.

CONCLUSION: Primary non-gestational uterine cervical choriocarcinoma may arise from germ cell tumor or epithelial tissue.

[MeSH-major] Choriocarcinoma, Non-gestational / pathology. Uterine Cervical Neoplasms / pathology

Genetic Alliance. consumer health - Choriocarcinoma.

MedlinePlus Health Information. consumer health - Cervical Cancer.

COS Scholar Universe. author profiles.

International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15925400.001).

[ISSN] 0090-8258

[Journal-full-title] Gynecologic oncology

[ISO-abbreviation] Gynecol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis.

Adjuvant radiotherapy after complete resection of localized, invasive thymic epithelial tumors is considered by many to be the standard of care, despite little supporting literature.

Analysis of data from 592 patients with completely resected stage II or III thymic epithelial tumors, however, revealed no statistically significant reduction in recurrence after adjuvant radiotherapy (odds ratio 1.05; 95% confidence interval: 0.63 to 1.75; p = 0.840).

[MeSH-major] Thymus Neoplasms / radiotherapy

[MeSH-minor] Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma / surgery. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Secondary Prevention

MedlinePlus Health Information. consumer health - Thymus Cancer.

COS Scholar Universe. author profiles.

PubMed Health. DARE review .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19379938.001).

[ISSN] 1552-6259

[Journal-full-title] The Annals of thoracic surgery

[ISO-abbreviation] Ann. Thorac. Surg.

[Language] eng

[Publication-type] Journal Article; Meta-Analysis; Review

[Publication-country] Netherlands

[Number-of-references] 42

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.

Circulating epithelial tumor cells (CETC) were quantified before and after each second cycle of the therapy regimen, between the anthracycline and the taxane block of the regimen and in some cases repeatedly during CMF treatment.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Epithelial Cells / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplastic Cells, Circulating / pathology

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

Hazardous Substances Data Bank. TAMOXIFEN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. EPIRUBICIN .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Breast. 2007 Apr;16(2):211-8 [17291754.001]

[Cites] Clin Chem Lab Med. 2001 Sep;39(9):811-7 [11601678.001]

[Cites] BMJ. 2005 Jan 29;330(7485):205-6 [15677633.001]

[Cites] Clin Cancer Res. 2001 Dec;7(12):4102-8 [11751508.001]

[Cites] Lancet. 1999 Jul 17;354(9174):197-202 [10421301.001]

[Cites] Breast Cancer Res Treat. 2003 Dec;82(3):199-206 [14703067.001]

[Cites] Cancer Res. 1999 Aug 1;59(15):3776-82 [10446995.001]

[Cites] Cancer. 2005 Mar 1;103(5):884-91 [15666325.001]

[Cites] Nat Med. 2005 Aug;11(8):824-5 [16079872.001]

[Cites] Ann Oncol. 2003 Jun;14(6):849-55 [12796021.001]

[Cites] Crit Rev Oncol Hematol. 2005 Sep;55(3):167-75 [16039867.001]

[Cites] N Engl J Med. 2005 Aug 25;353(8):793-802 [16120859.001]

[Cites] Exp Hematol. 2004 Oct;32(10):891-904 [15504544.001]

[Cites] BMJ. 2005 Jan 29;330(7485):217 [15649903.001]

[Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]

[Cites] World J Surg Oncol. 2005 Mar 31;3(1):18 [15801980.001]

[Cites] Eur J Surg Oncol. 2002 Sep;28(6):615-9 [12359196.001]

[Cites] Clin Cancer Res. 2005 Aug 1;11(15):5657; author reply 5657-8 [16061886.001]

[Cites] Clin Cancer Res. 2004 Feb 15;10(4):1392-400 [14977842.001]

[Cites] Anticancer Res. 2004 Nov-Dec;24(6):4211-6 [15736474.001]

[Cites] Clin Cancer Res. 2005 May 15;11(10):3678-85 [15897564.001]

[Cites] Breast Cancer Res. 2005;7(6):R975-9 [16280045.001]

[Cites] Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003372 [15846660.001]

[Cites] MMW Fortschr Med. 2002 Oct 10;144(41):37-9 [12474359.001]

[Cites] Clin Cancer Res. 2004 Dec 15;10(24):8152-62 [15623589.001]

(PMID = 17611779.001).

[ISSN] 1432-1335

[Journal-full-title] Journal of cancer research and clinical oncology

[ISO-abbreviation] J. Cancer Res. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Bridged-Ring Compounds; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 1605-68-1 / taxane; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gamma Knife surgery in the management of orbital tumors.

OBJECT: The authors evaluated the results they obtained using Gamma Knife surgery (GKS) in patients with orbital tumors.

METHODS: This is a retrospective clinical evaluation of 202 patients with orbital tumors who were treated with GKS between September 1995 and October 2008.

There were 84 meningiomas, 38 epithelial tumors of the lacrimal gland, 23 schwannomas, 18 malignant choroidal melanomas, 12 optic nerve gliomas, 11 orbital metastases, 10 pseudotumors of the orbit, 3 retinoblastomas, and 3 cases of fibromatosis.

The tumor margin dose ranged from 10 to 40 Gy.

RESULTS: At a median follow-up period of 34.5 ± 14.7 months (range 12-114 months), tumor shrinkage was observed in 118 patients (58.4%) and stable tumor size in 71 patients (35.1%).

Regularly scheduled neuroimaging studies demonstrated evidence of tumor progression in only 13 patients (6.4%): 9 of these patients underwent repeated GKS and 4 received surgical treatment.

CONCLUSIONS: Gamma Knife surgery provides an effective management strategy in patients with orbital tumors; it achieves excellent preservation of neurological function and is associated with few treatment-related complications.

[MeSH-major] Meningioma / surgery. Neurilemmoma / surgery. Optic Nerve Glioma / surgery. Orbital Neoplasms / surgery. Radiosurgery / instrumentation

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Meningeal Neoplasms / surgery. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21121785.001).

[ISSN] 1933-0693

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Ki67 was included as a measure of growth fraction of tumor cells.

METHODS: Digital video analysis images from tumor cell areas and tumor stromal areas were analyzed on formalin fixed, paraffin-embedded and immunohistochemical stained cancer specimens from 59 patients: 32 patients with metastases and 27 patients without clinical, biochemical, or radiological evidence of metastases within 10 years after diagnosis.

RESULTS: In primary cancers in the metastatic group, COX-2, TGF-beta and Ki67 were stronger expressed in epithelial tumor cell and tumor stromal areas compared with non-metastatic cancers (for all markers, p<0.0001).

High intensity of COX-2 staining in tumor areas was strongly associated with death from prostate cancer in univariate analyses (hazard ratio [HR] 95% CI, 4.0 (1.1-14.5)).

[MeSH-major] Cyclooxygenase 2 / metabolism. Interleukin-10 / metabolism. Ki-67 Antigen / metabolism. Prostatic Neoplasms / metabolism. Transforming Growth Factor beta / metabolism

[MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / metabolism. Carcinoma / mortality. Carcinoma / pathology. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Rectal Neoplasms / metabolism. Rectal Neoplasms / secondary. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / secondary

Genetic Alliance. consumer health - Prostate cancer.

Genetic Alliance. consumer health - Metastatic cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.

(PMID = 20409773.001).

[ISSN] 1877-783X

[Journal-full-title] Cancer epidemiology

[ISO-abbreviation] Cancer Epidemiol

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Transforming Growth Factor beta; 130068-27-8 / Interleukin-10; EC 1.14.99.1 / Cyclooxygenase 2

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.

BACKGROUND: Tumor angiogenesis is a dynamic process that plays a major role in cancer progression.

METHODS: Total VEGF protein levels were quantified by enzyme-linked immunosorbent assay (ELISA) in tumor tissue samples from surgical specimens of 65 patients with clear cell RCC.

At the cellular level the VEGF isoforms VEGFR-1 and VEGFR-2 mRNA were quantified by real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) in laser-microdissected tumoral epithelial as stromal cells and in corresponding normal tissue compartments.

In laser-microdissected epithelial cells, VEGF(121) and VEGFR-1 mRNA expressions were higher in RCC than in corresponding nontumoral kidney (P= .007 and P= .002, respectively); they were also higher in stromal cells of RCC compared with nontumoral kidney (P= .02 and P= .003, respectively).

There was no differential VEGFR-2 expression in epithelial or in stromal cells of tumoral or nontumoral kidney.

By immunofluorescent labeling VEGF and VEGFR-1 colocalized on RCC tumor epithelial and stromal cells.

CONCLUSIONS: Combined laser microdissection and quantitative RT-PCR, as triple immunofluorescent labeling, underlined the preferential expression of the most soluble VEGF isoform, VEGF(121), and its receptor VEGFR-1, but not VEGFR-2, in epithelial and stromal cells of RCC.

[MeSH-major] Carcinoma, Renal Cell / chemistry. Kidney Neoplasms / chemistry. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-1 / analysis

[MeSH-minor] Adult. Aged. Aged, 80 and over. Epithelial Cells / chemistry. Female. Fluorescent Antibody Technique. Humans. Keratins / analysis. Keratins / genetics. Male. Microdissection. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / chemistry. Vascular Endothelial Growth Factor Receptor-2 / analysis. Vascular Endothelial Growth Factor Receptor-2 / genetics

Genetic Alliance. consumer health - Renal cell carcinoma.

MedlinePlus Health Information. consumer health - Kidney Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18041056.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 68238-35-7 / Keratins; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Local expression of AT1R, AT2R, and angiotensin-converting enzyme (ACE) was investigated by immunohistochemistry in tumor and corresponding nontumor specimens obtained from 100 patients with gastric cancer, and compared with the ACE insertion/deletion gene polymorphism.

AT1R and AT2R were found in the tumor epithelial cells of 26 (26%) and 95 (95%) patients, respectively.

In intestinal type gastric cancer, its expression correlated with the N category (P = 0.009) and the International Union Against Cancer tumor stage (P = 0.024).

AT1R+ intestinal type gastric cancers had a larger number of lymph node metastases (P = 0.026), a higher International Union Against Cancer tumor stage (P = 0.032), and a shorter survival time (P = 0.009) than AT1R- tumors.

When the ACE genotype was included, the relative risk of having lymph node metastases increased considerably in AT1R+ tumors being heterozygous or homozygous for the ACE D allele (odds ratio, 19.00; 95% confidence interval, 1.45-248.24).

[MeSH-major] Adenocarcinoma / pathology. Angiotensin II / metabolism. Genetic Predisposition to Disease. Peptidyl-Dipeptidase A / genetics. Receptors, Angiotensin / metabolism. Stomach Neoplasms / pathology

MedlinePlus Health Information. consumer health - Stomach Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17548686.001).

[ISSN] 1055-9965

[Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Receptors, Angiotensin; 11128-99-7 / Angiotensin II; EC 3.4.15.1 / Peptidyl-Dipeptidase A

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We sought to determine the role of epithelial (tumor cell-derived) and stromal (host-derived) expression of MMPs in predicting the clinical outcome of patients with epithelial ovarian cancer (EOC).

EXPERIMENTAL DESIGN: MMP-2, MMP-9, and membrane type 1 (MT1)-MMP expression was evaluated using immunohistochemistry in 90 invasive EOCs, and samples were scored for epithelial and stromal staining.

RESULTS: High expression of MMP-2, MMP-9, and MT1-MMP in tumor epithelium was detected in 54%, 97%, and 100% of cases, and in stromal compartments, in 38%, 70%, and 38% of cases, respectively.

Kaplan-Meier analysis showed that high epithelial and stromal expression of MMP-2, MMP-9, and MT1-MMP were each significantly associated with shorter disease-specific survival (DSS; P < 0.01).

On tree-structured survival analysis, patients with strong epithelial MT1-MMP expression had the shortest DSS, whereas patients with moderate epithelial MT1-MMP and low stromal MMP-9 expression had the longest DSS (P < 0.01).

On multivariate analysis, high stromal expression of MMP-9 (P = 0.01) and MT1-MMP (P = 0.04), strong epithelial MT1-MMP (P = 0.01) and high stage (P = 0.04) were independent predictors of poor DSS.

Genetic Alliance. consumer health - Ovarian cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Breast Cancer Res Treat. 2000 Sep;63(2):105-15 [11097087.001]

[Cites] Clin Exp Metastasis. 1999;17(10):799-808 [11089877.001]

[Cites] Eur J Cancer. 2001 Nov;37(16):2040-9 [11597382.001]

[Cites] Trends Cell Biol. 2001 Nov;11(11):S37-43 [11684441.001]

[Cites] Gynecol Oncol. 2002 Jan;84(1):126-34 [11748988.001]

[Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45 [11988310.001]

[Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]

[Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]

[Cites] Surgery. 2002 Aug;132(2):220-5 [12219015.001]

[Cites] Clin Cancer Res. 2002 Sep;8(9):2924-32 [12231537.001]

[Cites] Eur J Gynaecol Oncol. 2003;24(5):417-20 [14584660.001]

[Cites] Gynecol Oncol. 2004 Feb;92(2):559-67 [14766248.001]

[Cites] Mol Cancer Res. 2004 Feb;2(2):73-80 [14985463.001]

[Cites] J Biol Chem. 2004 Apr 2;279(14):13564-74 [14729679.001]

[Cites] Am J Obstet Gynecol. 2004 Apr;190(4):899-909 [15118611.001]

[Cites] Clin Cancer Res. 2004 Oct 1;10(19):6512-21 [15475438.001]

[Cites] Lab Invest. 1983 Dec;49(6):636-49 [6317982.001]

[Cites] FASEB J. 1990 Apr 1;4(6):1577-90 [2180767.001]

[Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]

[Cites] Biometrics. 1992 Jun;48(2):411-25 [1637970.001]

[Cites] Breast Cancer Res Treat. 1993;24(3):185-93 [8435474.001]

[Cites] Lab Invest. 1993 Sep;69(3):312-21 [8377473.001]

[Cites] Int J Cancer. 1994 Feb 15;56(4):500-5 [8112886.001]

[Cites] J Cell Sci. 1994 Feb;107 ( Pt 2):477-86 [8207074.001]

[Cites] Int J Cancer. 1994 Jul 1;58(1):50-6 [8014015.001]

[Cites] J Histochem Cytochem. 1994 Jul;42(7):945-51 [8014478.001]

[Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2730-4 [7708715.001]

[Cites] Int J Cancer. 1996 Jan 3;65(1):57-62 [8543396.001]

[Cites] Int J Cancer. 1996 Feb 20;69(1):9-16 [8600068.001]

[Cites] J Biochem. 1996 Feb;119(2):209-15 [8882706.001]

[Cites] J Clin Oncol. 1996 Nov;14(11):2968-75 [8918494.001]

[Cites] Invasion Metastasis. 1996;16(3):150-9 [9186550.001]

[Cites] Cancer. 1997 Oct 15;80(8):1457-63 [9338470.001]

[Cites] Cell. 1997 Nov 14;91(4):439-42 [9390552.001]

[Cites] Hum Pathol. 1998 Feb;29(2):155-65 [9490275.001]

[Cites] Int J Oncol. 1998 Mar;12(3):569-76 [9472094.001]

[Cites] Br J Cancer. 1999 May;80(3-4):315-21 [10408832.001]

[Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]

[Cites] Gynecol Oncol. 1999 Oct;75(1):91-8 [10502432.001]

[Cites] Gynecol Oncol. 2004 Dec;95(3):437-48 [15581944.001]

[Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]

[Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]

[Cites] Cancer Res. 2005 Aug 1;65(15):6910-8 [16061675.001]

[Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]

[Cites] Gynecol Oncol. 2000 Jun;77(3):369-76 [10831344.001]

[Cites] Int J Oncol. 2000 Oct;17(4):673-81 [10995877.001]

[Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]

[Cites] Am J Clin Pathol. 2001 Apr;115(4):517-24 [11293899.001]

(PMID = 16551853.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA109298; United States / NCI NIH HHS / CA / 1P50CA83639; United States / NCI NIH HHS / CA / R01 CA110793; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA11079301; United States / NCI NIH HHS / CA / CA10929801

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14

[Other-IDs] NLM/ NIHMS310734; NLM/ PMC3202606

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This receptor is over-expressed in the majority of tumors of epithelial origin, including glioblastomas.

188Rhenium (188Re) constitutes an ideal radionuclide for imagining and radioimmunotherapy, and its toxicity is known, nevertheless, it is unknown if 188Os, as 188Re's daughter, has any local or systemic toxicity effect when it is administered intracerebrally for treating intracranial tumors.

Hazardous Substances Data Bank. OSMIUM, ELEMENTAL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15816360.001).

[ISSN] 0940-2993

[Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie

[ISO-abbreviation] Exp. Toxicol. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 2E7M255OPY / Osmium; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Pilomatricoma, also known as 'calcifying epithelioma of Malherbe', is a common skin adnexal tumor that mimics hair growth.

This aberration was corroborated by interphase fluorescence in situ hybridization, using a chromosome 18 pericentromeric probe, in the basaloid epithelial component of 7 of 11 pilomatricomas, including the index case.

Trisomy 18 was present in a small subset of cells, suggesting a role in pilomatricoma progression, rather than in tumor initiation.

We conclude that trisomy 18 is a consistent feature in pilomatricoma, suggesting that genes carried on this chromosome, such as that for the antiapoptotic oncoprotein BCL2, may have a role in the growth and differentiation of this benign self-limited tumor.

[MeSH-major] Chromosomes, Human, Pair 18. Hair Diseases / genetics. Pilomatrixoma / genetics. Skin Neoplasms / genetics. Trisomy

Genetic Alliance. consumer health - Trisomy 18.

MedlinePlus Health Information. consumer health - Hair Problems.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20495544.001).

[ISSN] 1530-0285

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Increased Raf phosphorylation was also observed in primary human breast cultures derived from ER-positive and ER-negative breast tumours.

AT1 receptor was found to be expressed in the cell membrane of breast tumour epithelial cells.

[MeSH-major] Breast Neoplasms / physiopathology. Receptor, Angiotensin, Type 1 / physiology. Receptors, Estrogen / physiology

[MeSH-minor] Cell Proliferation. Cell Survival. Cyclic AMP / metabolism. Female. Humans. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation. RNA, Small Interfering. Signal Transduction. Tumor Cells, Cultured

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Endocrinol. 2000 Oct;14(10):1649-60 [11043579.001]

[Cites] Circ Res. 2000 Nov 24;87(11):E44-52 [11090554.001]

[Cites] Endocrinology. 2000 Dec;141(12):4503-11 [11108261.001]

[Cites] Mol Endocrinol. 2002 Jan;16(1):70-84 [11773440.001]

[Cites] Mol Endocrinol. 2002 Jan;16(1):100-15 [11773442.001]

[Cites] J Steroid Biochem Mol Biol. 2002 Feb;80(2):231-8 [11897506.001]

[Cites] J Biol Chem. 2003 Jan 24;278(4):2701-12 [12421825.001]

[Cites] J Cell Physiol. 2003 Aug;196(2):370-7 [12811831.001]

[Cites] J Biol Chem. 2004 Jun 25;279(26):27008-16 [15090535.001]

[Cites] Br J Cancer. 2004 Nov 1;91(9):1687-93 [15477868.001]

[Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):398-404 [2166070.001]

[Cites] Endocrinology. 1992 Sep;131(3):1305-12 [1505465.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8517-21 [8078914.001]

[Cites] Nature. 1995 May 18;375(6528):247-50 [7746328.001]

[Cites] Hypertension. 1996 Mar;27(3 Pt 2):476-80 [8613189.001]

[Cites] EMBO J. 1996 Mar 15;15(6):1292-300 [8635462.001]

[Cites] Eur J Endocrinol. 1996 Sep;135(3):367-73 [8890730.001]

[Cites] J Biol Chem. 1997 May 2;272(18):11902-7 [9115251.001]

[Cites] Br J Cancer. 1997;75(9):1279-83 [9155046.001]

[Cites] Biochem Biophys Res Commun. 1997 Jun 9;235(1):99-102 [9196043.001]

[Cites] Endocrinology. 1997 Sep;138(9):4030-3 [9275096.001]

[Cites] Mol Endocrinol. 1999 Feb;13(2):307-19 [9973260.001]

[Cites] Endocrinology. 1999 Mar;140(3):1385-91 [10067866.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4686-91 [10200323.001]

[Cites] Biochem Biophys Res Commun. 1999 Sep 16;263(1):257-62 [10486286.001]

[Cites] Mol Endocrinol. 2004 Dec;18(12):2854-65 [15231873.001]

[Cites] Mol Endocrinol. 2005 Feb;19(2):277-89 [15486047.001]

[Cites] Steroids. 2005 May-Jun;70(5-7):361-3 [15862818.001]

[Cites] Mol Endocrinol. 2005 Aug;19(8):1951-9 [15705661.001]

[Cites] J Cell Physiol. 2000 Jul;184(1):27-36 [10825231.001]

[Cites] Mol Pharmacol. 2000 Sep;58(3):608-13 [10953055.001]

[Cites] Circ Res. 2000 Oct 13;87(8):677-82 [11029403.001]

(PMID = 16805920.001).

[ISSN] 1465-542X

[Journal-full-title] Breast cancer research : BCR

[ISO-abbreviation] Breast Cancer Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Receptor, Angiotensin, Type 1; 0 / Receptors, Estrogen; E0399OZS9N / Cyclic AMP; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases

[Other-IDs] NLM/ PMC1557727

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Prognosis of surgically treated thymic epithelial tumors].

This study was performed to clarify the prognosis of patients with surgically treated thymic epithelial tumors.

Pathologic review was done according to the WHO classification of tumors of the thymus.

Patients characteristics were: 76 male and 55 fimale; average age 53 (range 20-80) years; tumor stage was stage I in 42, stage II in 43, stage III in 23, stage IVa in 15, stage IVb in 1, and thymic carcinoma (squamous cell carcinoma) in 7 based on Masaoka's staging.

The prognosis of patients with thymic epithelial tumors after resection is thought to be determined by histologic classification and clinical invasiveness.

[MeSH-major] Carcinoma / surgery. Thymus Neoplasms / surgery

[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors. World Health Organization

MedlinePlus Health Information. consumer health - Thymus Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17147284.001).

[ISSN] 0301-4894

[Journal-full-title] Nihon Geka Gakkai zasshi

[ISO-abbreviation] Nihon Geka Gakkai Zasshi

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis.

Serum amyloid A (SAA) is an acute phase protein which is expressed primarily in the liver as a part of the systemic response to various injuries and inflammatory stimuli; its expression in ovarian tumors has not been described.

Here, we investigated the expression of SAA in human benign and malignant ovarian epithelial tumors.

Expression was increased gradually as epithelial cells progressed through benign and borderline adenomas to primary and metastatic adenocarcinomas.

[MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Serum Amyloid A Protein / genetics. Serum Amyloid A Protein / metabolism

[MeSH-minor] Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. CA-125 Antigen / blood. Cell Line, Tumor. Female. Humans. Middle Aged. Neoplasm Metastasis. Ovary / cytology. Ovary / metabolism. Ovary / pathology. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]

[Cites] Ann Intern Med. 1979 Sep;91(3):383-90 [289303.001]

[Cites] Scand J Immunol. 1984 Mar;19(3):193-8 [6200925.001]

[Cites] Biochem Biophys Res Commun. 1991 May 15;176(3):1100-5 [2039494.001]

[Cites] DNA Cell Biol. 1991 Nov;10(9):651-61 [1755958.001]

[Cites] J Biol Chem. 1992 Feb 25;267(6):3862-7 [1740433.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3186-90 [8159722.001]

[Cites] Genomics. 1994 Jan 15;19(2):228-35 [8188253.001]

[Cites] J Exp Med. 1994 Jul 1;180(1):203-9 [7516407.001]

[Cites] Am J Pathol. 1994 Sep;145(3):650-60 [8080047.001]

[Cites] J Immunol. 1995 Aug 1;155(3):1184-90 [7636186.001]

[Cites] Lab Invest. 1998 May;78(5):535-9 [9605178.001]

[Cites] J Histochem Cytochem. 1998 Dec;46(12):1377-84 [9815279.001]

[Cites] J Rheumatol. 1999 Apr;26(4):785-90 [10229397.001]

[Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]

[Cites] Eur J Immunol. 2005 Mar;35(3):718-26 [15724247.001]

[Cites] Biochem Biophys Res Commun. 2005 May 13;330(3):989-98 [15809093.001]

[Cites] Proteomics. 2005 Sep;5(14):3790-7 [16121334.001]

[Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]

[Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]

[Cites] Arthritis Rheum. 2006 Jan;54(1):105-14 [16385502.001]

[Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]

[Cites] J Immunol. 2006 Oct 15;177(8):5585-94 [17015746.001]

[Cites] Biomed Environ Sci. 2007 Feb;20(1):33-40 [17458139.001]

[Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]

[Cites] Biochem Biophys Res Commun. 2008 Apr 4;368(2):368-73 [18237545.001]

[Cites] FEBS Lett. 2008 Mar 5;582(5):579-85 [18243142.001]

[Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95 [18028381.001]

[Cites] J Clin Oncol. 2009 May 1;27(13):2199-208 [19307507.001]

[Cites] Br J Cancer. 2009 Jul 21;101(2):335-41 [19536090.001]

[Cites] Cancer. 2010 Feb 15;116(4):843-51 [20041483.001]

[Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88 [20082099.001]

[Cites] Eur Urol. 2010 May;57(5):859-66 [19747761.001]

[Cites] J Clin Pathol. 1986 Jul;39(7):794-7 [3734116.001]

[Cites] Curr Opin Hematol. 2000 Jan;7(1):64-9 [10608507.001]

[Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):405-8 [10679217.001]

[Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]

[Cites] Blood. 2002 Feb 15;99(4):1224-9 [11830469.001]

[Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]

[Cites] J Histochem Cytochem. 1984 Mar;32(3):322-8 [6363521.001]

(PMID = 20713982.001).

[ISSN] 1551-5044

[Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

[ISO-abbreviation] J. Histochem. Cytochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CA-125 Antigen; 0 / Serum Amyloid A Protein; 9007-41-4 / C-Reactive Protein

[Other-IDs] NLM/ PMC2958134

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

AIM: Anal cancer is a rare neoplasm.

RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular epithelioma associated with areas of Bowen's disease.

[MeSH-major] Anus Neoplasms / diagnosis. Sentinel Lymph Node Biopsy

[MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Recurrence

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18337684.001).

[ISSN] 1824-4785

[Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology

[ISO-abbreviation] Q J Nucl Med Mol Imaging

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Craniopharyngioma is histologically a benign epithelial tumor located in the supersellar cistern that often presents aggressive growth and repeated recurrence.

METHODS: The cohorts consisted of 32 patients with AE and 31 patients with SP tumor.

CONCLUSIONS: Microvascular density and VEGF in craniopharyngioma tissue have no correlation with prognosis of the tumor, which may be explained by the minimal blood circulation in the craniopharyngioma.

Adamantine epithelioma showed more tendency to recur than SP.

[MeSH-major] Craniopharyngioma / blood supply. Craniopharyngioma / metabolism. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / blood supply. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

Genetic Alliance. consumer health - Craniopharyngioma.

MedlinePlus Health Information. consumer health - Pituitary Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16904996.001).

[ISSN] 0090-3019

[Journal-full-title] Surgical neurology

[ISO-abbreviation] Surg Neurol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Lcn2 has been shown to induce the epithelial to mesenchymal transition (EMT) in breast cancer cells and to promote breast tumor invasion.

The potential roles of Lcn2 in epithelial tumors as well as leukemia are also reviewed and discussed here.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. IRON, ELEMENTAL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell. 2005 Dec 29;123(7):1293-305 [16377569.001]

[Cites] Biochem J. 2005 Oct 15;391(Pt 2):441-8 [16060857.001]

[Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]

[Cites] Int J Cancer. 2006 May 15;118(10):2490-7 [16381001.001]

[Cites] Mol Cell Proteomics. 2006 Aug;5(8):1471-83 [16733264.001]

[Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]

[Cites] J Clin Pathol. 2007 May;60(5):555-61 [17412867.001]

[Cites] Breast Cancer Res Treat. 2008 Apr;108(3):389-97 [17554627.001]

[Cites] J Clin Invest. 2008 Apr;118(4):1468-78 [18317594.001]

[Cites] J Proteome Res. 2008 Apr;7(4):1481-9 [18311905.001]

[Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]

[Cites] Leuk Lymphoma. 2008 May;49(5):984-8 [18464118.001]

[Cites] Cancer Res. 2008 Aug 1;68(15):6100-8 [18676832.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14058-63 [18768801.001]

[Cites] Oncogene. 2008 Oct 16;27(47):6110-9 [18663364.001]

[Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]

[Cites] Int J Cancer. 2008 Dec 15;123(12):2856-64 [18798264.001]

[Cites] J Exp Clin Cancer Res. 2008;27:83 [19077278.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8 [19237579.001]

[Cites] J Immunol. 2009 Apr 15;182(8):4947-56 [19342674.001]

[Cites] EMBO J. 2009 Apr 8;28(7):866-76 [19229297.001]

[Cites] J Histochem Cytochem. 2009 May;57(5):513-21 [19188485.001]

[Cites] PLoS Genet. 2009 Apr;5(4):e1000460 [19390610.001]

[Cites] Lab Invest. 2009 May;89(5):531-48 [19308044.001]

[Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):9-24 [11058743.001]

[Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):298-307 [11058770.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9265-70 [11459932.001]

[Cites] Science. 2001 Aug 3;293(5531):829-34 [11486081.001]

[Cites] Cancer Res. 2001 Aug 15;61(16):5979-84 [11507038.001]

[Cites] J Biol Chem. 2001 Oct 5;276(40):37258-65 [11486009.001]

[Cites] Cancer Res. 2001 Nov 1;61(21):7792-7 [11691794.001]

[Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]

[Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]

[Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]

[Cites] Mol Cell. 2002 Nov;10(5):1033-43 [12453412.001]

[Cites] Mol Cell. 2002 Nov;10(5):1045-56 [12453413.001]

[Cites] Cell. 2003 Apr 18;113(2):207-19 [12705869.001]

[Cites] Int J Oncol. 2003 Sep;23(3):681-91 [12888904.001]

[Cites] Cancer Res. 2003 Dec 15;63(24):8614-22 [14695172.001]

[Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]

[Cites] Int J Cancer. 2004 Oct 20;112(1):100-12 [15305381.001]

[Cites] J Proteome Res. 2004 Sep-Oct;3(5):1042-55 [15473694.001]

[Cites] FEBS Lett. 1992 Dec 21;314(3):386-8 [1281792.001]

[Cites] J Biol Chem. 1993 May 15;268(14):10425-32 [7683678.001]

[Cites] Gut. 1996 Mar;38(3):414-20 [8675096.001]

[Cites] Biochem J. 1996 Aug 15;318 ( Pt 1):1-14 [8761444.001]

[Cites] J Dent Res. 1996 Aug;75(8):1553-63 [8906123.001]

[Cites] Genomics. 1997 Oct 1;45(1):17-23 [9339356.001]

[Cites] Cancer Lett. 1998 Jan 9;122(1-2):209-14 [9464512.001]

[Cites] Int J Cancer. 1998 Dec 18;79(6):565-72 [9842963.001]

[Cites] Histochem J. 1999 Jul;31(7):433-41 [10475571.001]

[Cites] Nature. 2004 Dec 16;432(7019):917-21 [15531878.001]

[Cites] FEBS Lett. 2005 Jan 31;579(3):773-7 [15670845.001]

[Cites] J Clin Invest. 2005 Mar;115(3):610-21 [15711640.001]

[Cites] J Biol Chem. 2005 Apr 8;280(14):13641-7 [15691834.001]

[Cites] Oncogene. 2005 May 5;24(20):3246-56 [15735695.001]

[Cites] Clin Cancer Res. 2005 Aug 1;11(15):5390-5 [16061852.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1834-9 [16446425.001]

(PMID = 19571677.001).

[ISSN] 1551-4005

[Journal-full-title] Cell cycle (Georgetown, Tex.)

[ISO-abbreviation] Cell Cycle

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA118764-05; United States / NCI NIH HHS / CA / R01 CA118764; United States / NCI NIH HHS / CA / R01 CA118764-05

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Estrogen Receptor alpha; 0 / LCN2 protein, human; 0 / Ligands; 0 / Lipocalins; 0 / Proto-Oncogene Proteins; E1UOL152H7 / Iron; EC 3.4.24.35 / Matrix Metalloproteinase 9

[Other-IDs] NLM/ NIHMS278018; NLM/ PMC3381736

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In clinical tissue all samples demonstrated cytoplasmic tumour epithelial HRGbeta1 protein staining, with expression correlating with EGFR positivity and activation of both AKT and ERK1/2.

This may have implications for the effectiveness of anti-EGFR therapies in breast cancer as HRGbeta1 is enriched in many EGFR-positive breast tumours.

[MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Breast Neoplasms / drug therapy. Drug Resistance, Neoplasm. Neuregulin-1 / pharmacology. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology. Tamoxifen / pharmacology

[MeSH-minor] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Blotting, Western. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cell Proliferation. Dimerization. Female. Humans. Immunoprecipitation. Mitogen-Activated Protein Kinases / metabolism. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptor, ErbB-3 / metabolism. Signal Transduction. Trastuzumab

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. TAMOXIFEN .

Hazardous Substances Data Bank. Trastuzumab .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Cancer. 2001 Jul 20;95(4):247-54 [11400118.001]

[Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]

[Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]

[Cites] Cancer Res. 2002 Jan 1;62(1):200-7 [11782378.001]

[Cites] Ann Oncol. 2002 Jan;13(1):65-72 [11863114.001]

[Cites] Cancer Res. 2002 Jun 1;62(11):3151-8 [12036928.001]

[Cites] Oncologist. 2002;7 Suppl 4:2-8 [12202782.001]

[Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]

[Cites] Mol Cancer Res. 2003 Jan;1(3):165-75 [12556556.001]

[Cites] Endocrinology. 2003 Mar;144(3):1032-44 [12586780.001]

[Cites] Clin Cancer Res. 2003 Apr;9(4):1274-83 [12684395.001]

[Cites] Oncogene. 2003 May 8;22(18):2812-22 [12743604.001]

[Cites] Clin Cancer Res. 2003 Oct 1;9(12):4340-6 [14555504.001]

[Cites] J Pathol. 2004 Jun;203(2):672-80 [15141382.001]

[Cites] Breast Cancer Res Treat. 2004 Sep;87(2):167-80 [15377841.001]

[Cites] Clin Exp Metastasis. 2004;21(3):201-12 [15387370.001]

[Cites] Mol Cell Biol. 1994 Jun;14(6):3550-8 [7515147.001]

[Cites] Breast Cancer Res Treat. 1994 Jan;29(1):117-25 [7912565.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6 [8058768.001]

[Cites] Int J Cancer. 1994 Dec 1;59(5):619-28 [7960234.001]

[Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]

[Cites] Cancer Res. 1996 Mar 15;56(6):1457-65 [8640840.001]

[Cites] Mol Cell Biol. 1996 Oct;16(10):5276-87 [8816440.001]

[Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]

[Cites] Breast Cancer Res Treat. 1997 Aug;45(1):75-80 [9285119.001]

[Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):757-63 [9677338.001]

[Cites] J Biol Chem. 1998 Oct 23;273(43):28238-46 [9774445.001]

[Cites] Oncogene. 1998 Oct 15;17(15):1949-57 [9788438.001]

[Cites] Cancer Res. 1999 Apr 1;59(7):1620-5 [10197638.001]

[Cites] J Cell Sci. 1999 Sep;112 Pt 18:3081-90 [10462524.001]

[Cites] Endocr Relat Cancer. 2004 Dec;11(4):793-814 [15613453.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):397-405 [15671571.001]

[Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]

[Cites] Clin Cancer Res. 1999 Oct;5(10):2877-83 [10537356.001]

[Cites] Oncogene. 1999 Oct 28;18(44):6050-62 [10557094.001]

[Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]

[Cites] Int J Cancer. 2000 Aug 15;87(4):487-98 [10918187.001]

[Cites] Int J Oncol. 2000 Oct;17(4):629-41 [10995872.001]

[Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]

[Cites] Breast Cancer Res. 2005;7(4):R570-9 [15987464.001]

[Cites] Clin Exp Metastasis. 2004;21(8):665-84 [16035612.001]

[Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S173-82 [16113094.001]

[Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111 [16113104.001]

[Cites] Endocrinology. 2005 Nov;146(11):4609-18 [16037379.001]

[Cites] Cancer Res. 2006 Feb 1;66(3):1418-26 [16452197.001]

[Cites] Cancer Res. 2006 Feb 1;66(3):1640-7 [16452223.001]

[Cites] Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45 [16531062.001]

[Cites] Future Oncol. 2005 Apr;1(2):221-34 [16555994.001]

[Cites] Future Oncol. 2005 Aug;1(4):461-6 [16556022.001]

[Cites] Breast Cancer Res Treat. 2006 Mar;96(2):131-46 [16261397.001]

[Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]

(PMID = 17686159.001).

[ISSN] 1465-542X

[Journal-full-title] Breast cancer research : BCR

[ISO-abbreviation] Breast Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Hormonal; 0 / Neuregulin-1; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 094ZI81Y45 / Tamoxifen; 155646-83-6 / heregulin beta1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; P188ANX8CK / Trastuzumab; S65743JHBS / gefitinib

[Other-IDs] NLM/ PMC2206726

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-throughput analysis of chromosome translocations and other genome rearrangements in epithelial cancers.

Genes that are broken or fused by structural changes to the genome are an important class of mutation in the leukemias and sarcomas but have been largely overlooked in the common epithelial cancers.

This reveals more clearly than before the extent to which many cancer genomes are rearranged and how much these rearrangements contribute to the mutational burden of epithelial tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]

[Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]

[Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]

[Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]

[Cites] Science. 2007 Sep 14;317(5844):1500 [17872428.001]

[Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]

[Cites] Nature. 2009 Dec 24;462(7276):1005-10 [20033038.001]

[Cites] Nat Genet. 2008 Jun;40(6):722-9 [18438408.001]

[Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]

[Cites] Genome Res. 2009 Feb;19(2):167-77 [19056696.001]

[Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]

[Cites] J Pathol. 2010 Jan;220(2):244-54 [19921709.001]

[Cites] Oncogene. 2008 May 22;27(23):3345-59 [18084325.001]

(PMID = 20236477.001).

[ISSN] 1756-994X

[Journal-full-title] Genome medicine

[ISO-abbreviation] Genome Med

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2873797

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oncogenic gene fusions in epithelial carcinomas.

New discoveries regarding recurrent chromosomal aberrations in epithelial tumors have challenged the view that gene fusions play a minor role in these cancers.

This work has generated new insights into the molecular subtypes of tumors and highlighted important advances in bioinformatics, sequencing, and microarray technology as tools for gene fusion discovery.

Nevertheless, the majority of chromosomal abnormalities in epithelial cancers remain uncharacterized, underscoring the limitations of our knowledge of carcinogenesis and the requirement for further research.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

SciCrunch. KEGG: Data: Disease Annotation .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cytogenet Genome Res. 2007;118(2-4):157-65 [18000366.001]

[Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]

[Cites] Oncogene. 2008 Jan 10;27(3):253-63 [17637754.001]

[Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]

[Cites] PLoS Comput Biol. 2008 Apr;4(4):e1000051 [18404202.001]

[Cites] Mod Pathol. 2008 May;21 Suppl 2:S37-43 [18437172.001]

[Cites] Nat Genet. 2008 Jun;40(6):685-6 [18509307.001]

[Cites] Clin Cancer Res. 2008 Jun 1;14(11):3380-5 [18519767.001]

[Cites] Clin Cancer Res. 2008 Jun 1;14(11):3395-400 [18519769.001]

[Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):815-25 [18505969.001]

[Cites] Cancer Res. 2008 Jul 1;68(13):4971-6 [18593892.001]

[Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]

[Cites] Genome Res. 2008 Jul;18(7):1143-9 [18326688.001]

[Cites] Science. 2008 Aug 15;321(5891):956-60 [18599741.001]

[Cites] Mod Pathol. 2008 Dec;21(12):1451-60 [18500259.001]

[Cites] Neoplasia. 2008 Feb;10(2):177-88 [18283340.001]

[Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]

[Cites] Nat Genet. 2004 Apr;36(4):331-4 [15054488.001]

[Cites] Oncogene. 2004 Apr 29;23(20):3634-41 [15077183.001]

[Cites] Cancer. 2004 Jun 1;100(11):2362-6 [15160339.001]

[Cites] Br J Cancer. 2004 Aug 16;91(4):732-8 [15238980.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13257-61 [15326299.001]

[Cites] Science. 1990 Feb 16;247(4944):824-30 [2406902.001]

[Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]

[Cites] Science. 1991 Nov 29;254(5036):1371-4 [1720570.001]

[Cites] Nat Genet. 1997 Feb;15(2):170-4 [9020842.001]

[Cites] Clin Cancer Res. 1998 Jan;4(1):223-8 [9516975.001]

[Cites] Mod Pathol. 2008 Feb;21(2):67-75 [18065961.001]

[Cites] Genes Chromosomes Cancer. 2003 May;37(1):58-71 [12661006.001]

[Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]

[Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):81-99 [9739011.001]

[Cites] J Natl Cancer Inst. 1960 Jul;25:85-109 [14427847.001]

[Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):463-8 [15483076.001]

[Cites] Semin Cancer Biol. 2005 Jun;15(3):224-35 [15826837.001]

[Cites] Clin Lab Med. 2005 Jun;25(2):363-78 [15848741.001]

[Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):350-66 [15880352.001]

[Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]

[Cites] Endocrinology. 2006 Jan;147(1):367-76 [16179407.001]

[Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]

[Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]

[Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]

[Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]

[Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13808-13 [11717438.001]

[Cites] Am J Pathol. 2001 Dec;159(6):1987-92 [11733348.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4477-82 [11930005.001]

[Cites] Cancer Cell. 2002 Nov;2(5):367-76 [12450792.001]

[Cites] Cancer Res. 2003 Jan 15;63(2):304-7 [12543779.001]

[Cites] Nat Genet. 2003 Feb;33(2):208-13 [12539049.001]

[Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):717-9 [16575875.001]

[Cites] Neoplasia. 2006 Jun;8(6):465-9 [16820092.001]

[Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]

[Cites] Nat Immunol. 2006 Oct;7(10):1082-91 [16936731.001]

[Cites] Science. 2006 Sep 29;313(5795):1929-35 [17008526.001]

[Cites] Neoplasia. 2006 Oct;8(10):826-32 [17032499.001]

[Cites] Oncogene. 2007 Jan 11;26(2):277-83 [16832349.001]

[Cites] Cancer Res. 2007 Feb 1;67(3):919-29 [17283122.001]

[Cites] Neoplasia. 2007 Feb;9(2):166-80 [17356713.001]

[Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]

[Cites] Neoplasia. 2007 May;9(5):443-54 [17534450.001]

[Cites] Oncogene. 2007 Jul 5;26(31):4596-9 [17237811.001]

[Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]

[Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]

[Cites] Clin Cancer Res. 2007 Sep 1;13(17):5103-8 [17785564.001]

[Cites] Cancer Res. 2007 Sep 1;67(17):7991-5 [17804708.001]

[Cites] J Cell Biochem. 2007 Oct 1;102(2):320-31 [17722107.001]

[Cites] J Clin Pathol. 2007 Nov;60(11):1238-43 [17259299.001]

(PMID = 19233641.001).

[ISSN] 1879-0380

[Journal-full-title] Current opinion in genetics & development

[ISO-abbreviation] Curr. Opin. Genet. Dev.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / R01 CA132874; United States / NCI NIH HHS / CA / CA132874-01A1; United States / NCI NIH HHS / CA / CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568-06A10016; United States / NCI NIH HHS / CA / R01 CA132874-01A1; United States / NCI NIH HHS / CA / CA069568-110020; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / CA069568-06A10016; United States / NCI NIH HHS / CA / U01 CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Oncogene Proteins, Fusion

[Number-of-references] 69

[Other-IDs] NLM/ NIHMS102222; NLM/ PMC2676581

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basaloid epithelial tumors of dogs and cats.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] Vet Clin Pathol. 2010 Mar;39(1):96-8 [19645743.001]

(PMID = 20624263.001).

[ISSN] 1939-165X

[Journal-full-title] Veterinary clinical pathology

[ISO-abbreviation] Vet Clin Pathol

[Language] ENG

[Publication-type] Comment; Letter

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phenotypic plasticity of the ovarian surface epithelium: TGF-beta 1 induction of epithelial to mesenchymal transition (EMT) in vitro.

Ovarian surface epithelium (OSE) is the most conceivable cell origin of epithelial ovarian carcinomas.

Unlike many other epithelial tumors, the precancerous lesion acquires expression of epithelial markers, e.g.

E-cadherin and claudins, suggesting that OSE cells undergo mesenchymal to epithelial transition (MET) during transformation.

Recent findings indicate that TGF-β1, a prototypic stimulus of epithelial to mesenchymal transition (EMT), i.e. reverse to MET, is produced at significant amounts in the intact ovary.

In the present study, we therefore investigated whether TGF-β1 changes the OSE phenotype accordingly, focusing on epithelial junction proteins and transcriptional EMT regulators quantified by real-time RT-PCR and Western blotting in cultured normal human OSE.

Early OSE passages were found to paradoxically express de novo E-cadherin and also establish tight junctions exhibiting claudin-1 (but not claudin-3 and -4) and occludin.

Stimulation with TGF-β1 (100 ng/ml) for 3-5 d down-regulated all these epithelial markers including Crumbs3 and also prevented the formation of an epithelial barrier This was accompanied by sustained expression of Snail and N-cadherin and transient expression of Slug, whereas Zeb1 (zinc finger E-box binding homeobox 1) and Twist mRNA levels were not significantly changed.

In conclusion, TGF-β1 enforces the mesenchymal phenotype of OSE cells in vitro by an EMT-like process, leading to an altered molecular composition of the epithelial junction complex that partly coincides with the expression pattern of the native OSE.

This suggests a potential role of TGF-β1-induced EMT in OSE under physiological conditions and possibly also in epithelial ovarian tumorigenesis.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Endocrinology. 2010 Nov;151(11):5092-4 [20962057.001]

(PMID = 20844000.001).

[ISSN] 1945-7170

[Journal-full-title] Endocrinology

[ISO-abbreviation] Endocrinology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CRB3 protein, human; 0 / Cadherins; 0 / Claudin-1; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / OCLN protein, human; 0 / Occludin; 0 / Transforming Growth Factor beta1

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.

PURPOSE: In carcinomas, invasive tumor growth is accompanied by desmoplastic stroma reaction and facilitated by epithelial-mesenchymal transition (EMT) of cancer cells.

We investigated the prognostic significance of the EMT indicator proteins periostin and vimentin in comparison with versican, a putative indicator of the opposite mechanism mesenchymal-epithelial transition (MET), and to the desmoplasia proteins collagen and elastin in non-small cell lung cancer (NSCLC).

EXPERIMENTAL DESIGN: Tumor of 533 patients with surgically resected NSCLC was used for analysis of stromal and epithelial protein expression by immunohistochemistry (EMT-MET proteins) and Elastica van Gieson histochemical staining (collagen and elastin).

High expression of periostin in either stroma or tumor epithelia, independently scored by two pathologists, correlated with male gender, higher stage, higher pT category, and larger tumor size, and in only stroma with tumor relapse.

High expression of versican in either stroma or epithelia as well as of stromal collagen had fewer but concordant associations with advanced tumor and periostin, respectively.

CONCLUSIONS: Because up-regulation is frequently observed in the stromal and epithelial tumor compartment, EMT-MET indicator proteins may be integrated in progression models of NSCLC.

[MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / metabolism. Vimentin / biosynthesis

[MeSH-minor] Age Factors. Aged. Cell Differentiation / physiology. Collagen / biosynthesis. Elastin / biosynthesis. Epithelial Cells / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mesoderm / metabolism. Middle Aged. Prognosis. Sex Factors. Tissue Array Analysis. Versicans / biosynthesis

Genetic Alliance. consumer health - Lung Cancer.

Genetic Alliance. consumer health - Non-small cell lung cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19010860.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / Vimentin; 126968-45-4 / Versicans; 9007-34-5 / Collagen; 9007-58-3 / Elastin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The expression of fascin in epithelial neoplasms has been described only recently, and the role of fascin in esophageal squamous cell carcinoma (ESCC) is still unknown.

RESULTS: In immunohistochemical study, the intensity of fascin expression was usually increased in the tumor compared with that in normal epithelium.

The fascin immunoreactive rate was associated with extent of the tumor (P = 0.002) and lymph node metastasis (P = 0.003).

[MeSH-major] Carcinoma, Squamous Cell / pathology. Carrier Proteins / genetics. Esophageal Neoplasms / pathology. Microfilament Proteins / genetics

[MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Movement. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Transfection

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Esophageal Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15814639.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 146808-54-0 / fascin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

However, CD154 treatment of carcinoma cells expressing proteasome-dependent but TAP-independent Ags from the EBV-encoded BRLF1 and BMLF1 failed to increase tumor cell lysis by specific CTLs.

Taken together, these observations demonstrate the functional expression of CD40 in epithelial tumors of the cervix and support the clinical exploitation of the CD40 pathway for the treatment of cervical cancer through its multiple effects on tumor cell growth, apoptosis, and immune recognition.

[MeSH-major] Antigens, CD40 / metabolism. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. T-Lymphocytes, Cytotoxic / immunology. Uterine Cervical Neoplasms / immunology. Uterine Cervical Neoplasms / metabolism

[MeSH-minor] Antigen Presentation / drug effects. Antigen Presentation / immunology. CD40 Ligand / metabolism. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / immunology. Cervical Intraepithelial Neoplasia / metabolism. Female. Flow Cytometry. HeLa Cells. Humans. Immunoblotting. Immunohistochemistry. Mitogen-Activated Protein Kinase Kinases / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. NF-kappa B / drug effects. NF-kappa B / metabolism. Papillomavirus Infections. Proteasome Endopeptidase Complex / drug effects. Proteasome Endopeptidase Complex / immunology. Signal Transduction / drug effects. Signal Transduction / immunology

MedlinePlus Health Information. consumer health - Cervical Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15611226.001).

[ISSN] 0022-1767

[Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)

[ISO-abbreviation] J. Immunol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD40; 0 / NF-kappa B; 147205-72-9 / CD40 Ligand; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex